Apolipoprotein E promotes primary resistance to AR-targeted therapy via inducing TRIM25-mediated AR ubiquitination and sensitizes immunotherapy in prostate cancer
Theranostics · 21.04.2025 · 15 (12) · 5572-5591
DOI: 10.7150/thno.109994 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 21.04.2025. Verfasst von Chaofan Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China. Hauptthemen laut MEDLINE: Receptors, Androgen, Drug Resistance, Neoplasm, Apolipoproteins E, Prostatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.
- Department of Urology, Sir RunRun Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.
- Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- School of Computer Science and Technology, Huazhong University of Science and Technology, China.
Zitieren
APA
Liu, C., Wang, X., Li, Q., Gao, X., Zeng, K., Li, B., Miao, J., Zheng, B., Liu, J., Wang, Z., Yuan, X., & Liu, B. (2025). Apolipoprotein E promotes primary resistance to AR-targeted therapy via inducing TRIM25-mediated AR ubiquitination and sensitizes immunotherapy in prostate cancer. Theranostics, 15(12), 5572-5591. https://doi.org/10.7150/thno.109994
Vancouver
Liu C, Wang X, Li Q, Gao X, Zeng K, Li B, et al. Apolipoprotein E promotes primary resistance to AR-targeted therapy via inducing TRIM25-mediated AR ubiquitination and sensitizes immunotherapy in prostate cancer. Theranostics. 2025;15(12):5572-5591. doi:10.7150/thno.109994
BibTeX
@article{Liu2025,
author = {Liu, Chaofan and Wang, Xi and Li, Qinyu and Gao, Xintao and Zeng, Kai and Li, Beining and Miao, Jianping and Zheng, Bolong and Liu, Jihong and Wang, Zhihua and Yuan, Xianglin and Liu, Bo},
title = {Apolipoprotein E promotes primary resistance to AR-targeted therapy via inducing TRIM25-mediated AR ubiquitination and sensitizes immunotherapy in prostate cancer},
journal = {Theranostics},
year = {2025},
volume = {15},
number = {12},
pages = {5572--5591},
doi = {10.7150/thno.109994}
}
EUVIMED